GSC
ABCL icon

Ground Swell Capital’s AbCellera Biologics ABCL Stock Holding History

Ground Swell Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,820
Closed -$55.2K – 147
2026
Q1 		$55.2K Buy
+15,820
New +$56.9K 0.11% 79

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Ground Swell Capital's ABCL Position: Q2 2026 in Review

Ground Swell Capital sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 15,820 shares — an estimated $55.2K sold.

Ground Swell Capital first reported a position in ABCL in Q1 2026 and held it in 1 quarter. The position peaked at $55.2K in Q1 2026. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Ground Swell Capital reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Ground Swell Capital sold 15,820 AbCellera Biologics shares in Q2 2026, an estimated $55.2K.
  • Ground Swell Capital first reported a position in AbCellera Biologics in Q1 2026 and held it in 1 quarter.
  • Ground Swell Capital's AbCellera Biologics position peaked at $55.2K in Q1 2026.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.